Inicio > BIGG > Resultado de la búsqueda

    Resultados: 2

    Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients

    Sancho, JM; Duarte, R; Medina, L; Querol, S; Marín, P; Sureda, A.
    Med. clín. (Barc); 147 (5), 2016
    "BACKGROUND AND OBJECTIVE: Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. Plerixafor, a reversible inhibitor of the binding of s...
    Compuestos Heterocíclicos, Receptores CXCR4, Movilización de Célula Madre Hematopoyética, Linfoma, Mieloma Múltiple, Trasplante de Células Madre de Sangre Periférica, Receptores CXCR4/antagonistas & inhibidores, Trasplante Autólogo, Mieloma Múltiple/terapia, Linfoma/terapia
    Texto completo

    SIE, SIES, GITMO revised guidelines for the management offollicular lymphoma

    Zinzani, Pier Luigi; Marchetti, Monia; Billio, Atto; Barosi, Giovanni; Carella, Angelo Michele; Lazzarino, Mario; Martelli, Maurizio; Rambaldi, Alessandro; Rigacci, Luigi; Tarella, Corrado; Vitolo, Umberto; Tura, Sante.
    Am. j. hematol; 90 (1), 2005
    By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...
    Anticuerpos Monoclonales, Anticuerpos, Anticuerpos Monoclonales de Origen Murino/uso terapéutico, Antineoplásicos, Esquema de Medicación, Trasplante de Células Madre Hematopoyéticas, Linfoma Folicular/patología, Linfoma/terapia, Estadificación de Neoplasias, Rituximab, Factores de Tiempo
    Texto completo